Fabian Buller is the CBO of Neurimmune, a Swiss clinical stage biotech company translating human immune memory into next generation antibody therapeutics. Fabian Buller is an experienced biotech executive with 8 years of professional experience in biotech and pharma. Prior to his position at Neurimmune, Fabian Buller served as Director New Ventures at Johnson & Johnson Innovation as well as Director Business Development of Covagen AG. He was instrumental in securing a number of major Biotech-Pharma deals including the sale of Covagen to J&J. Fabian Buller, a chemist by training, holds a PhD degree from the Institute of Chemistry and Applied Biosciences at ETH Zurich.